Please use this identifier to cite or link to this item: https://doi.org/10.3390/nano11020497
DC FieldValue
dc.titleSynthesis and characterization of chitosan-based nanodelivery systems to enhance the anticancer effect of sorafenib drug in hepatocellular carcinoma and colorectal adenocarcinoma cells
dc.contributor.authorRuman, Umme
dc.contributor.authorBuskaran, Kalaivani
dc.contributor.authorPastorin, Giorgia
dc.contributor.authorMasarudin, Mas Jaffri
dc.contributor.authorFakurazi, Sharida
dc.contributor.authorHussein, Mohd Zobir
dc.date.accessioned2022-10-11T08:03:44Z
dc.date.available2022-10-11T08:03:44Z
dc.date.issued2021-02-16
dc.identifier.citationRuman, Umme, Buskaran, Kalaivani, Pastorin, Giorgia, Masarudin, Mas Jaffri, Fakurazi, Sharida, Hussein, Mohd Zobir (2021-02-16). Synthesis and characterization of chitosan-based nanodelivery systems to enhance the anticancer effect of sorafenib drug in hepatocellular carcinoma and colorectal adenocarcinoma cells. Nanomaterials 11 (2) : 1-28. ScholarBank@NUS Repository. https://doi.org/10.3390/nano11020497
dc.identifier.issn2079-4991
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/232145
dc.description.abstractThe formation of two nanodelivery systems, Sorafenib (SF)-loaded chitosan (SF-CS) and their folate-coated (SF-CS-FA) nanoparticles (NPs), were developed to enhance SF drug delivery on human Hepatocellular Carcinoma (HepG2) and Colorectal Adenocarcinoma (HT29) cell lines. The ionic gelation method was adopted to synthesize the NPs. The characterizations were performed by DLS, FESEM, TEM, XRD, TGA, FTIR, and UV-visible spectroscopy. It was found that 83.7 ± 2.4% and 87.9 ± 1.1% of encapsulation efficiency; 18.2 ± 1.3% and 19.9 ± 1.4% of loading content; 76.3 ± 13.7 nm and 81.6 ± 12.9 nm of hydrodynamic size; 60–80 nm and 70–100 nm of TEM; and FESEM sizes of near-spherical shape were observed, respectively, for SF-CS and SF-CS-FA nanoparticles. The SF showed excellent release from the nanoparticles under pH 4.8 PBS solution, indicating a good delivery system for tumor cells. The cytotoxicity study revealed their better anticancer action towards HepG2 and HT29 cell lines compared to the free sorafenib. Moreover, both NPs systems showed negligible toxicity to normal Human Dermal Fibroblast adult cells (HDFa). This is towards an enhanced anticancer drug delivery system with sustained-release properties for better cancer management. © 2021 by the author. Licensee MDPI, Basel, Switzerland.
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2021
dc.subjectCancer
dc.subjectCell lines
dc.subjectChitosan-nanoparticles
dc.subjectDrug-delivery
dc.subjectFolic acid
dc.subjectHDFa
dc.subjectHepG2
dc.subjectHT29
dc.subjectSorafenib
dc.subjectTherapeutic
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.description.doi10.3390/nano11020497
dc.description.sourcetitleNanomaterials
dc.description.volume11
dc.description.issue2
dc.description.page1-28
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_nano11020497.pdf4.75 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons